Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035599195> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2035599195 endingPage "305" @default.
- W2035599195 startingPage "303" @default.
- W2035599195 abstract "In Parkinson's disease (PD), management of L-3,4-dihydroxyphenylalanine (l-DOPA)-related complications, such as l-DOPA induced dyskinesia and psychosis, remains inadequate, which poses a significant burden on the quality of life of patients. We have shown, in the hemi-parkinsonian rat model of PD, that the selective serotonin type 3 (5-HT3) receptor antagonists ondansetron and granisetron decreased the severity of established dyskinesia, and ondansetron even attenuated the development of dyskinesia. Here, we seek to confirm these favourable data on dyskinesia and to explore the effect of ondansetron on the severity of psychosis-like behaviours (PLBs) in the gold standard model of PD, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned non-human primate. We first determined the pharmacokinetic profile of ondansetron in the marmoset. Subsequently, six MPTP-lesioned marmosets were administered l-DOPA chronically until they exhibited stable and reproducible dyskinesia and PLBs upon each administration of l-DOPA. On behavioural assessment days, ondansetron (0.01, 0.1 and 1 mg/kg) or vehicle was administered in conjunction with l-DOPA, and the severity of dyskinesia, PLBs and parkinsonism was evaluated. Ondansetron 0.1 mg/kg alleviated global dyskinesia severity by 73% (P < 0.0001) and decreased duration of on-time with disabling dyskinesia by 88% (P = 0.0491). Ondansetron 0.1 mg/kg reduced the severity of global PLBs by 80% (P < 0.0001) and suppressed on-time with disabling PLBs (P = 0.0213). Ondansetron enhanced the anti-parkinsonian action of l-DOPA, reducing global parkinsonism by 53% compared to l-DOPA (P = 0.0004). These results suggest that selective blockade of the 5-HT3 receptor with ondansetron may be an effective approach to alleviate l-DOPA-related complications." @default.
- W2035599195 created "2016-06-24" @default.
- W2035599195 creator A5006219897 @default.
- W2035599195 creator A5019566094 @default.
- W2035599195 creator A5027859841 @default.
- W2035599195 creator A5056771320 @default.
- W2035599195 creator A5079154835 @default.
- W2035599195 creator A5079271973 @default.
- W2035599195 date "1987-06-01" @default.
- W2035599195 modified "2023-09-27" @default.
- W2035599195 title "Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain" @default.
- W2035599195 cites W1974912123 @default.
- W2035599195 cites W1980094166 @default.
- W2035599195 doi "https://doi.org/10.1016/0014-2999(87)90450-x" @default.
- W2035599195 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2442006" @default.
- W2035599195 hasPublicationYear "1987" @default.
- W2035599195 type Work @default.
- W2035599195 sameAs 2035599195 @default.
- W2035599195 citedByCount "109" @default.
- W2035599195 countsByYear W20355991952017 @default.
- W2035599195 countsByYear W20355991952021 @default.
- W2035599195 crossrefType "journal-article" @default.
- W2035599195 hasAuthorship W2035599195A5006219897 @default.
- W2035599195 hasAuthorship W2035599195A5019566094 @default.
- W2035599195 hasAuthorship W2035599195A5027859841 @default.
- W2035599195 hasAuthorship W2035599195A5056771320 @default.
- W2035599195 hasAuthorship W2035599195A5079154835 @default.
- W2035599195 hasAuthorship W2035599195A5079271973 @default.
- W2035599195 hasConcept C126322002 @default.
- W2035599195 hasConcept C170493617 @default.
- W2035599195 hasConcept C2776525014 @default.
- W2035599195 hasConcept C2777170512 @default.
- W2035599195 hasConcept C2778674702 @default.
- W2035599195 hasConcept C2778938600 @default.
- W2035599195 hasConcept C2779134260 @default.
- W2035599195 hasConcept C2779734285 @default.
- W2035599195 hasConcept C2780405171 @default.
- W2035599195 hasConcept C2780580376 @default.
- W2035599195 hasConcept C42219234 @default.
- W2035599195 hasConcept C71924100 @default.
- W2035599195 hasConcept C98274493 @default.
- W2035599195 hasConceptScore W2035599195C126322002 @default.
- W2035599195 hasConceptScore W2035599195C170493617 @default.
- W2035599195 hasConceptScore W2035599195C2776525014 @default.
- W2035599195 hasConceptScore W2035599195C2777170512 @default.
- W2035599195 hasConceptScore W2035599195C2778674702 @default.
- W2035599195 hasConceptScore W2035599195C2778938600 @default.
- W2035599195 hasConceptScore W2035599195C2779134260 @default.
- W2035599195 hasConceptScore W2035599195C2779734285 @default.
- W2035599195 hasConceptScore W2035599195C2780405171 @default.
- W2035599195 hasConceptScore W2035599195C2780580376 @default.
- W2035599195 hasConceptScore W2035599195C42219234 @default.
- W2035599195 hasConceptScore W2035599195C71924100 @default.
- W2035599195 hasConceptScore W2035599195C98274493 @default.
- W2035599195 hasIssue "2" @default.
- W2035599195 hasLocation W20355991951 @default.
- W2035599195 hasLocation W20355991952 @default.
- W2035599195 hasOpenAccess W2035599195 @default.
- W2035599195 hasPrimaryLocation W20355991951 @default.
- W2035599195 hasRelatedWork W137083958 @default.
- W2035599195 hasRelatedWork W1942166399 @default.
- W2035599195 hasRelatedWork W1955121811 @default.
- W2035599195 hasRelatedWork W2006912446 @default.
- W2035599195 hasRelatedWork W2064767312 @default.
- W2035599195 hasRelatedWork W2264451885 @default.
- W2035599195 hasRelatedWork W2530418047 @default.
- W2035599195 hasRelatedWork W2554582392 @default.
- W2035599195 hasRelatedWork W2789545224 @default.
- W2035599195 hasRelatedWork W3095759448 @default.
- W2035599195 hasVolume "138" @default.
- W2035599195 isParatext "false" @default.
- W2035599195 isRetracted "false" @default.
- W2035599195 magId "2035599195" @default.
- W2035599195 workType "article" @default.